ISO/FDIS-18562-1:2024(E)

ISO-<u>/</u>TC-_121/SC-_3

ISO TC 121/SC 3/WG 13

2023-11-27

Secretariat:-_ANSI

Date: 2023-12-08

Biocompatibility evaluation of breathing gas pathways in healthcare applications —

Part 1: Evaluation and testing within a risk management process

Évaluation de la biocompatibilité des voieschemins de gaz respiratoiresrespiratoire utilisés dans les applicationsle domaine de soins dela santé —

Partie 1: Évaluation et essais au sein <u>d'und'un</u> processus de gestion du risque

ISO/FDIS 18562-

https://standards.iteh.ai/catalog/standards/sist/a5264ee9-b1c2-4448-bef1-2b2816985e35/iso-fdis-18562-1

FDIS stage

ISO/FDIS 18562-1:2024(E)

© ISO 2024 2023

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office

Case postale 56 • CP 401 • Ch. de Blandonnet 8

CH-12111214 Vernier, Geneva-20 Tel.Phone: + 41 22 749 01 11

Fax + 41 22 749 09 47

E-mail: copyright@iso.org

Web www.iso.org

Website: www.iso.org

Published in Switzerland-

iTeh Standards (https://standards.iteh.ai) Document Preview

ISO/FDIS 18562-1

https://standards.iteh.ai/catalog/standards/sist/a5264ee9-b1c2-4448-bef1-2b2816985e35/iso-fdis-18562-1

Contents

<u>For</u>	<u>eword</u>	Error! Bookmark not defined.	
<u>Int</u>	roduction	Error! Bookmark not defined.	
1	Scope	Error! Bookmark not defined.	
2	Normative references	Error! Bookmark not defined.	
3	Terms and definitions	<u></u> Error! Bookmark not defined.	
4 General principles applying to biocompatibility evaluation of medical devices Error! Bookmark not defined.			
4.1	General	Error! Bookmark not defined.	
4.2	Type tests	Error! Bookmark not defined.	
4.3	Biocompatibility hazard identification	<u></u> Error! Bookmark not defined.	
4.4	Extent of risk assessment	Error! Bookmark not defined.	
<u>4.5</u>	Biological evaluation plan	Error! Bookmark not defined.	
4.6	Selection of tests	<u></u> Error! Bookmark not defined.	
4.7	Subsequent evaluation	Error! Bookmark not defined.	
<u>5</u>	Contamination of breathing gas from gas pathways	<u></u> Error! Bookmark not defined.	
<u>5.1</u>	Duration of contact	Error! Bookmark not defined.	
<u>5.2</u>	Particulate matter (PM) emissions	Error! Bookmark not defined.	
<u>5.3</u>	Volatile organic substance emissions	<u></u> Error! Bookmark not defined.	
<u>5.4</u>	Leachables in condensate	Error! Bookmark not defined.	
D	Adjustment of exposure dose and inhalation dose for different particles and inhalation dose for different particles.		
6.1	General considerations <u>ISO/FDIS 18562-1</u>	<u></u> Error! Bookmark not defined.	
	Adjustment for different patient groups		
7	Deriving tolerable exposure (TE) for VOS	<u></u> Error! Bookmark not defined.	
7.1	General process	Error! Bookmark not defined.	
	For medical devices intended for limited exposure use (≤2		
	24 h but <30 d)		
	For medical devices intended for long-term exposure (≥30		
8	Determining values for leachables in condensate		
	General		
	Adjustments for different patient groups		
	Exposure dose estimate for condensate		
9	Risk control		
<u>10</u>	Benefit-risk analysis		
<u>11</u>	Biological evaluation report		
	formative) Rationale and guidance		
-	formative) Reference to the IMDRF essential principles and okmark not defined.	labelling guidances Error!	
<u>(in</u>	formative) Reference to the essential principles	Error! Bookmark not defined.	

ISO/FDIS 18562-1:2023(E)

<u>(informative) Terminology — Alphabetized index of defined terms</u>Error! Bookmark not defined.

<u>Bibliography</u>
______Error! Bookmark not defined.

4.1	General 12
4.2	Type tests 13
4.3	Biocompatibility hazard identification 14
4.4	Extent of risk assessment 15
4.5	Biological evaluation plan 15
4.6	Selection of tests 17
4.7	Subsequent evaluation 18
5.1	Duration of contact 19
5.2	Particulate matter (PM) emissions 20
5.3	Volatile organic substance emissions 20
5.4	Leachables in condensate 20
6.1	General considerations 21
6.2	Adjustment for different patient groups 21
7.1	General process 22 iTeh Standards
7.2 but <3	For <i>medical devices</i> intended for limited exposure use (≤24 h) and prolonged exposure use (>24 h) 0 d) — 22
7.3	For <i>medical devices</i> intended for long-term exposure (≥30 d) 23
8.1	General 23
8.2	Adjustments for different patient groups 24
83	Exposure dose estimate for condensate - 24 120 4440 kg to also 16005 and the 1956

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO document should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

ISO draws attention to the possibility that the implementation of this document may involve the use of (a) patent(s). ISO takes no position concerning the evidence, validity or applicability of any claimed patent rights in respect thereof. As of the date of publication of this document, ISO had not received notice of (a) patent(s) which may be required to implement this document. However, implementers are cautioned that this may not represent the latest information, which may be obtained from the patent database available at www.iso.org/patents. ISO shall not be held responsible for identifying any or all such patent rights.

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 121, Anaesthetic and respiratory equipment, Subcommittee SC 3, Lung ventilators and related equipment, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 215, Respiratory and anaesthetic equipment, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This second edition cancels and replaces the first edition (ISO 18562-1:2017), which has been technically revised.

The main changes are as follows:

- added informative mapping annexes to relevant regulatory requirements;
- clarified terms and definitions used in the document;
- expanded the *patient* groups to include: premature, small child, child, and adolescent;
- introduction of inhalation dose;
- the *threshold of toxicological concern* is changed;
- expanded the range of volatile organic substances that are tested;
- clarified the appropriate breathing gas volumes to be used in testing for VOS; and

ISO/FDIS 18562-1:2023(E)

— clarified the appropriate breathing gas volumes to be used in the analysis.

A list of all parts in the ISO 18562 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

iTeh Standards (https://standards.iteh.ai) Document Preview

ISO/FDIS 18562-1

https://standards.iteh.ai/catalog/standards/sist/a5264ee9-b1c2-4448-bef1-2b2816985e35/iso-fdis-18562-1

Introduction

This document represents the application of the best-known science, in order to improve *patient* safety, by addressing the *risk* of potentially hazardous substances being conveyed to the *patient* by the gas stream.

This document is intended to cover the biological evaluation of *gas pathways* of *medical devices* within a *risk management process*, as part of the overall *medical device* evaluation and development. This approach combines the review and evaluation of existing data from all sources with, where necessary, the selection and application of additional tests.

In general, the ISO 10993 series is intended to cover the biological evaluation of *medical devices*. However, the ISO 10993 series does not sufficiently address the biological evaluation of the *gas pathways* of *medical devices*.

Before this document was developed, some *authorities having jurisdiction* interpreted the ISO 10993-1:2009, Table A.1 to mean that as materials in the *gas pathway* form "indirect contact" with the *patient*, they should be subjected to tests equivalent to those required for tissue contact parts of *medical devices*. This interpretation can lead to tests that are not optimized for evaluation of *gas pathways* including possible *hazards* not being detected.

ISO 10993-_1:2018 states that it is not intended to provide a rigid set of test methods as this might result in an unnecessary constraint on the development and use of novel *medical devices*. ISO 10993-_1:2018 also states where a particular application warrants it, experts in the product or in the area of application concerned can choose to establish specific tests and criteria, described in a product-specific vertical standard. This new series of standards is intended to address the specific needs for the evaluation of *gas pathways* that are not adequately covered by ISO 10993-_1:2018.

This document provides a guide to the development of a biological evaluation plan that minimizes the number and exposure of test animals by giving preference to chemical constituent testing and *in vitro* models.

The initial version of this series of standards was intended to cover only the most commonly found potentially harmful substances. It was felt that it was best to get a functioning document published that would test for the bulk of the currently known substances of interest. With the use of the *TTC* (threshold of toxicological concern) approach, this document has the potential to be used to assess the safety of essentially any compound released from the gas pathways of respiratory medical devices, with very few exceptions (e.g. PCBs, dioxins), and not just the most commonly found potentially harmful substances.

ISO₋_18562-1 does not address all possible biological *hazards* that can be associated with *gas pathways*. Other, additional evaluations can be appropriate. These evaluations can require <u>futher further</u> *risk control* before finishing the biological evaluation.

Future parts of this series might be added to this series to address other relevant aspects of biological testing including additional contamination that might arise from the *gas pathway* because of the presence of drugs and anaesthetic agents added to the gas stream, and potential contamination by emission of inorganic gases such as ozone, CO, CO_2 , and NO_x .

NOTE Some *authorities having jurisdiction* require evaluation of these *risks* as part of a biological evaluation.

This document has been prepared in consideration of:

- ——the Essential Principles of Safety and Performance of Medical Devices and IVD Medical Devices, IMDRF/GRRP WG/N47:2018^[15] as indicated in Annex B;
- the Labelling Principles for Medical Devices and IVD Medical Devices, IMDRF/GRRP WG/N52:2019[16] as indicated in Annex B;
- the essential principles of safety and performance of a medical device according to ISO 16142-1:2016 as indicated in Annex C; and

ISO/FDIS 18562-1:2023(E)

— the general safety and performance requirements of a *medical device* according to regulation (EU) $2017/745^{[17]}$.

In this document, the following verbal forms are used:

- "shall" indicates a requirement;
- "should" indicates a recommendation;
- "may" indicates a permission;
- "can" indicates a possibility or capability.

iTeh Standards (https://standards.iteh.ai) Document Preview

ISO/FDIS 18562-1

https://standards.iteh.ai/catalog/standards/sist/a5264ee9-b1c2-4448-bef1-2b2816985e35/iso-fdis-18562-1

Biocompatibility evaluation of breathing gas pathways in healthcare applications —

Part 1:

Evaluation and testing within a risk management process

1 Scope

This document specifies:

- the general principles governing the biological evaluation within a *risk management process* of the *gas pathways* of a *medical device*, its parts or *accessories*, which are intended to provide respiratory care or supply substances via the respiratory tract to a *patient* in all environments;
- the general categorization of *gas pathways* based on the nature and duration of their contact with the gas stream;
- the evaluation of existing relevant data from all sources;
- the identification of gaps in the available data set on the basis of a *risk analysis*;
- the identification of additional data sets necessary to analyse the biological safety of the *gas pathway*;
- the assessment of the biological safety of the *gas pathway*.

This document covers general principles regarding *biocompatibility* assessment of *medical device* materials, which make up the *gas pathway*, in *normal use* and *normal condition*. This document does not cover biological *hazards* arising from mechanical damage.

The other parts of ISO 18562 cover specific tests that address potentially hazardous substances that are added to the respirable gas stream and establish acceptance criteria for these substances.

This document addresses potential contamination of the gas stream arising from the *gas pathways* within the *medical device*, which might then be conducted to the *patient*.

This document applies over the *expected lifetime* of the *medical device* when operated according to the instructions for use. This includes degradation arising from exposure to environmental conditions as well as cleaning, disinfection and sterilisation (i.e. *processing*). It also includes user action or inaction (omission) that leads to an unintended or unexpected outcome (result) (i.e. *use error*). It does not include conscious/intentional action or inaction that violates the instructions for use and is beyond reasonable *risk control* by the *manufacturer* (i.e. *abnormal use*).

This document does not address biological evaluation of the surfaces of *medical devices* that have direct contact with the *patient* or *user*. The requirements for direct contact surfaces are found in the ISO 10993 series.

Medical devices, parts or *accessories* containing *gas pathways* that are addressed by this document include, but are not limited to, ventilators, anaesthesia workstations (including gas mixers), breathing systems, oxygen conserving equipment, oxygen concentrators, nebulizers, low-pressure hose assemblies, humidifiers, heat and moisture exchangers, respiratory gas monitors, respiration monitors, masks, medical respiratory personal protective equipment^{[25][27][30-32]}, mouth pieces, resuscitators, breathing

tubes, breathing system filters, and Y-pieces as well as any breathing *accessories* intended to be used with such *medical devices*. The enclosed chamber of an incubator, including the mattress, and the inner surface of an oxygen hood are considered to be *gas pathways* and are also addressed by this document.

This document does not address contamination already present in the gas supplied from the gas sources while *medical devices* are in *normal use*.

EXAMPLE Contamination arriving at the *medical device* from gas sources such as *medical gas pipeline systems* (including the non-return valves in the pipeline outlets), outlets of pressure regulators connected or integral to a medical gas cylinder, or room air taken into the *medical device* is not addressed by ISO 18562 (all parts).

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993-1:2018, Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process

ISO 10993-17:2023, Biological evaluation of medical devices — Part 17: Establishment of allowable limits for leachable substances

ISO 14971:2019, Medical devices — Application of risk management to medical devices

ISO 18562-2:2024 ISO 18562-2:—1, Biocompatibility evaluation of breathing gas pathways in healthcare applications — Part 2: Tests for emissions of particulate matter

ISO 18562-3:2024ISO 18562-3:—², Biocompatibility evaluation of breathing gas pathways in healthcare applications — Part 3: Tests for emissions of volatile organic substances

ISO 18562 4:2024<u>ISO 18562-4:—</u>³, Biocompatibility evaluation of breathing gas pathways in healthcare applications — Part 4: Tests for leachables in condensate 562-1

43 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminology databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at https://www.iso.org/obp
- IEC Electropedia: available at https://www.electropedia.org/

NOTE For convenience, an alphabetized index of terms and their sources used in this document is found in Annex D.

© ISO 2024 - All rights reserved

¹ Under preparation. Stage at the time of publication: ISO/FDIS 18562-2:2023.

² Under preparation. Stage at the time of publication: ISO/FDIS 18562-3:2023.

³ Under preparation. Stage at the time of publication: ISO/FDIS 18562-4:2023.

3.1

abnormal use

conscious, deliberate act or deliberate omission of an act that is counter to or violates *normal use* and is also beyond any further reasonable means of *user interface*-related *risk control* by the *manufacturer*

EXAMPLE-____Reckless use or sabotage or intentional deliberate disregard of information for SAFETY are such acts.

Note 1 to-entry:-An intended but erroneous action that is not abnormal use is considered a type of use error.

Note 2 to-_entry:-_Abnormal use does not relieve the manufacturer from considering non-user interface-related means of risk control.

Note 3 to entry: Figure 1 shows the relationships of the types of use.




Figure 1 — Relationship of the types of use

[SOURCE: IEC 62366-1+AMD1:2020, 3.1, modified — deleted note 1.]

3.2

accessory

item, intended specifically by its *manufacturer*, to be used together with one or more *medical devices* to specifically enable or assist those *medical devices* to be used in accordance with their *intended use*

Note 1 to-entry:-An accessory is typically a consumable or separate item for use with one or more medical devices.

Note 2 to-entry:-Some authorities having jurisdiction consider an accessory to be a medical device.

Note 3 to-entry:-Some authorities having jurisdiction have a different definition of accessory.

[SOURCE: ISO 20417:2021, 3.1]

3.3

accompanying information

information accompanying or marked on a *medical device* or *accessory* for the user or those accountable for the installation, use, *processing*, maintenance, decommissioning and disposal of the *medical device* or *accessory*, particularly regarding safe use

Note-1-to entry:-The accompanying information shall be regarded as part of the medical device or accessory.

Note-_2-_to entry:-_The *accompanying information* can consist of the label, marking, instructions for use, technical description, installation manual, quick reference guide, etc.

Note-_3-_to entry:-_*Accompanying information* is not necessarily a written or printed document but could involve auditory, visual, or tactile materials and multiple media types (e.g., CD/DVD-ROM, USB stick, website).

© ISO 2024 - All rights reserved

ISO/FDIS-18562-1:20242023(E)

[SOURCE: ISO 20417:2021, 3.2, modified — deleted note 4.]

3.4

authority having jurisdiction

regulatory authority

governmental agency or office assigned to oversee the regulation of a regulated product within a country, jurisdiction, or assigned territory

[SOURCE: ISO 16142-1:2016, 3.1]

3.5

benefit

positive impact or desirable outcome of the use of a *medical device* on the health of an individual, or a positive impact on *patient* management or public health

Note-1-to-entry:-Benefits can include positive impact on clinical outcome, the patient's quality of life, outcomes related to diagnosis, positive impact from diagnostic devices on clinical outcomes, or positive impact on public health.

[SOURCE: ISO 14971:2019, 3.2]

3.6

biocompatibility

ability of a *medical device*, *accessory* or material to perform with an appropriate host response in a specific application

Note-1-to-entry:-A medical device or accessory may produce some level of adverse effect, but that level may be determined to be acceptable when considering the *benefit* provided.

[SOURCE: ISO 10993-1:2018, 3.1, modified — added accessory and note.]

3.7

essential principles /catalog/standards/sist/a5264ee9-b1c2-4448-bef1-2b2816985e35/iso-fdis-18562-1

essential principles of safety and performance

fundamental high-level requirements that when complied with ensure a medical device or accessory is safe and performs as intended

[SOURCE: ISO 16142-1:2016, 3.3, modified — added 'or *accessory*'.]

3.8

expected lifetime

expected service life

period specified by the *manufacturer* during which the *medical device* or *accessory* is expected to maintain basic safety and essential performance

Note-1-to entry:-The expected lifetime can be affected by the stability of the medical device or accessory or by the materials in the *medical device* or *accessory*.

Note-2-to entry:-Maintenance, repairs or upgrades (e.g., safety or security modifications) can be necessary during the expected lifetime.

Note-3-to entry:-Some medical devices have an absolute lifetime (e.g., 5 y), whereas other medical devices (e.g., software) have a relative lifetime (e.g., the time between two major releases).

© ISO 2024 - All rights reserved